SLC5A2 and heart failure: Irrespective of diabetic status, baseline HbA1c, or degree of glucose lowering, selective SGLT2 inhibitors reduce the risk of worsening heart failure or cardiovascular death in patients with existing heart failure and reduced ejection fraction (McMurray et al., 2019; Packer et al., 2020; Petrie et al., 2020; Anker et al., 2021).